Will newer tyrosine kinase inhibitors have an impact in AML?

Research output: Contribution to journalArticle

Abstract

FLT3 inhibition has been a goal of acute myeloid leukemia (AML) therapy since FLT3 mutations were discovered to have a role in AML. Several FLT3 inhibitors have been developed in the last several years, beginning with less potent, less selective agents. The newer FLT3 inhibitors appear to be more potent in vivo and have shown more promise than the older agents in monotherapy trials.

Original languageEnglish (US)
Pages (from-to)489-494
Number of pages6
JournalBest Practice and Research: Clinical Haematology
Volume23
Issue number4
DOIs
StatePublished - Dec 2010

Fingerprint

Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Mutation
Therapeutics

Keywords

  • AC220
  • Acute myeloid leukemia
  • AML
  • FLT3
  • Inhibitor
  • KW-2449
  • Lestaurtinib
  • Midostaurin
  • Sorafenib

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Cite this

Will newer tyrosine kinase inhibitors have an impact in AML? / Levis, Mark J.

In: Best Practice and Research: Clinical Haematology, Vol. 23, No. 4, 12.2010, p. 489-494.

Research output: Contribution to journalArticle

@article{a79a53dfc752461798019b95b4a92b45,
title = "Will newer tyrosine kinase inhibitors have an impact in AML?",
abstract = "FLT3 inhibition has been a goal of acute myeloid leukemia (AML) therapy since FLT3 mutations were discovered to have a role in AML. Several FLT3 inhibitors have been developed in the last several years, beginning with less potent, less selective agents. The newer FLT3 inhibitors appear to be more potent in vivo and have shown more promise than the older agents in monotherapy trials.",
keywords = "AC220, Acute myeloid leukemia, AML, FLT3, Inhibitor, KW-2449, Lestaurtinib, Midostaurin, Sorafenib",
author = "Levis, {Mark J}",
year = "2010",
month = "12",
doi = "10.1016/j.beha.2010.09.008",
language = "English (US)",
volume = "23",
pages = "489--494",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "4",

}

TY - JOUR

T1 - Will newer tyrosine kinase inhibitors have an impact in AML?

AU - Levis, Mark J

PY - 2010/12

Y1 - 2010/12

N2 - FLT3 inhibition has been a goal of acute myeloid leukemia (AML) therapy since FLT3 mutations were discovered to have a role in AML. Several FLT3 inhibitors have been developed in the last several years, beginning with less potent, less selective agents. The newer FLT3 inhibitors appear to be more potent in vivo and have shown more promise than the older agents in monotherapy trials.

AB - FLT3 inhibition has been a goal of acute myeloid leukemia (AML) therapy since FLT3 mutations were discovered to have a role in AML. Several FLT3 inhibitors have been developed in the last several years, beginning with less potent, less selective agents. The newer FLT3 inhibitors appear to be more potent in vivo and have shown more promise than the older agents in monotherapy trials.

KW - AC220

KW - Acute myeloid leukemia

KW - AML

KW - FLT3

KW - Inhibitor

KW - KW-2449

KW - Lestaurtinib

KW - Midostaurin

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=78649931161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649931161&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2010.09.008

DO - 10.1016/j.beha.2010.09.008

M3 - Article

C2 - 21130412

AN - SCOPUS:78649931161

VL - 23

SP - 489

EP - 494

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 4

ER -